BMEA · Biomea Fusion, Inc.

This disclosure represents Biomea Fusion’s first public reporting of clinical data for icovamenib in type 1 diabetes, derived from the Phase 2 COVALENT-112 trial. The 52% increase in mean C-peptide AUC at Week 12 in the early-diagnosis cohort (0–3 years) is a clinically meaningful signal of beta-cell preservation — a primary therapeutic goal in T1D where endogenous insulin production declines progressively. The trial employed a defined inclusion criterion (C-peptide ≥0.2 nmol/L), maintained standard background therapy, and used placebo control with a 4:1 randomization ratio (32:8), supporting internal validity. While the filing confirms statistical significance (p < 0.05) for the primary endpoint, it omits details on secondary endpoints, adverse events profile, or durability beyond Week 12 — all of which will be critical for regulatory engagement and next-study design. The referenced Exhibit 99.1 — a slide deck titled 'Icovamenib in Type 1 Diabetes: COVALENT' — is furnished but not filed, limiting its use in liability contexts under Section 18 of the Exchange Act. No financial results, guidance, or capital allocation plans are disclosed; materiality stems entirely from de-risking a novel mechanism in a high-unmet-need indication with potential for disease modification. Next steps appear aligned with investigator sites named (Barbara Davis Center, Joslin, UT Health San Antonio, University of Miami), suggesting preparation for a subsequent Phase 2 study, though no timeline or protocol specifics are provided in the filing.